Latest Scolr Pharma Inc (SCLR) Headlines RedHil
Post# of 3
Posted On: 03/11/2014 7:07:56 AM
Latest Scolr Pharma Inc (SCLR) Headlines
RedHill Biopharma Provides Update on RHB-102 Development and Intellectual Property
GlobeNewswire - Fri Mar 07, 6:00AM CST
-- RHB-102 is a proprietary once-daily oral antiemetic
Dental Pain - Pipeline Review, H2 2013
M2 - Fri Dec 13, 2:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/xwnzmd/dental_pain) has announced the addition of the "Dental Pain - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for Dental Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dental Pain. Dental Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Dental Pain. - A review of the Dental Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dental Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Dental Pain. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Dental Pain pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - Array BioPharma - Bayer - Eli Lilly and Company - Iroko Pharmaceuticals - NeuroDiscovery - Pfizer - SCOLR Pharma For more information visit http://www.researchandmarkets.com/research/xw...ental_pain About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
RedHill Biopharma Provides Update on RHB-102 Development and Intellectual Property
GlobeNewswire - Fri Mar 07, 6:00AM CST
-- RHB-102 is a proprietary once-daily oral antiemetic
Dental Pain - Pipeline Review, H2 2013
M2 - Fri Dec 13, 2:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/xwnzmd/dental_pain) has announced the addition of the "Dental Pain - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for Dental Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dental Pain. Dental Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Dental Pain. - A review of the Dental Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dental Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Dental Pain. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Dental Pain pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - Array BioPharma - Bayer - Eli Lilly and Company - Iroko Pharmaceuticals - NeuroDiscovery - Pfizer - SCOLR Pharma For more information visit http://www.researchandmarkets.com/research/xw...ental_pain About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
(0)
(0)